Bioversys N
Develops novel therapeutics to combat antimicrobial resistance in life-threatening infections.
BIOV | SW
Overview
Corporate Details
- ISIN(s):
- CH0210362643 (+1 more)
- LEI:
- 894500UFIGC75NPZEZ68
- Country:
- Switzerland
- Address:
- Hochbergerstrasse 60C, 4057 Basel
- Website:
- https://www.bioversys.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Bioversys is a clinical-stage biopharmaceutical company dedicated to the research and development of novel small-molecule therapeutics to combat the global threat of Antimicrobial Resistance (AMR). The company specializes in developing drugs that utilize novel modes of action to target life-threatening, drug-resistant bacteria. Its clinical pipeline addresses high-priority pathogens and includes candidates for serious hospital-acquired infections (BV100), multi-drug resistant Tuberculosis (Alpibectir), and S. aureus infections (BV200). By targeting novel bacterial pathways, Bioversys aims to provide innovative solutions for significant unmet medical needs in infectious diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-10 07:00 |
Regulatory News Service
BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network
|
English | 26.0 KB | ||
| 2025-11-10 01:00 |
Regulatory News Service
BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network
|
English | 19.5 KB | ||
| 2025-11-06 07:00 |
Regulatory News Service
Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in …
|
English | 13.1 KB | ||
| 2025-11-06 01:00 |
Regulatory News Service
Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in …
|
English | 12.1 KB | ||
| 2025-11-05 07:00 |
Regulatory News Service
Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york
|
English | 6.9 KB | ||
| 2025-11-05 01:00 |
Report Publication Announcement
Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york
|
English | 5.6 KB | ||
| 2025-11-03 07:00 |
Board/Management Information
Bioversys announces appointment of anti-infective expert Dr. Daniel Ritz as Chi…
|
English | 9.0 KB | ||
| 2025-11-03 01:00 |
Board/Management Information
Bioversys announces appointment of anti-infective expert Dr. Daniel Ritz as Chi…
|
English | 7.9 KB | ||
| 2025-09-10 07:00 |
Earnings Release
Bioversys reports corporate highlights and key financials for the first half 20…
|
English | 24.8 KB | ||
| 2025-09-10 02:00 |
Earnings Release
Bioversys reports corporate highlights and key financials for the first half 20…
|
English | 23.3 KB | ||
| 2025-09-10 00:00 |
Interim Report
BioVersys Half Year Report 2025
|
English | 1.8 MB | ||
| 2025-08-27 07:00 |
Regulatory News Service
BioVersys receives EMA Orphan Designation for the combination of alpibectir and…
|
English | 21.9 KB | ||
| 2025-08-27 02:00 |
Regulatory News Service
BioVersys receives EMA Orphan Designation for the combination of alpibectir and…
|
English | 15.9 KB | ||
| 2025-07-02 07:00 |
M&A Activity
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECT…
|
English | 21.3 KB | ||
| 2025-07-02 02:00 |
M&A Activity
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECT…
|
English | 16.1 KB |
Automate Your Workflow. Get a real-time feed of all Bioversys N filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Bioversys N
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Bioversys N via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
